DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0378425A1 Wilde Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0378425A1 Wilde Et Al US 20140378425A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0378425A1 Wilde et al. (43) Pub. Date: Dec. 25, 2014 (54) BOMARKERS FOR DIAGNOSIS OF LUNG Publication Classification DISEASES AND METHODS OF USE THEREOF (51) Int. C. CI2O I/68 (2006.01) (71) Applicant: Veracyte, Inc., South San Francisco, CA A 6LX3/97 (2006.01) (US) A613 L/52 (2006.01) A613 L/442 (2006.01) (72) Inventors: Jonathan I. Wilde, South San Francisco, A 6LX3/573 (2006.01) CA (US); Sharlene Velichko, South San (52) U.S. C. Francisco, CA (US); Catalin CPC .......... CI2O I/6883 (2013.01); A61 K3I/4412 Barbacioru, South San Francisco, CA (2013.01); A61 K3I/573 (2013.01); A61 K (US); James Diggans, South San 31/52 (2013.01); A61K3I/197 (2013.01); Francisco, CA (US); Giulia Kennedy, C12O 2600/158 (2013.01); C12O 2600/I 12 South San Francisco, CA (US) (2013.01) USPC .. 514/179; 506/9:435/7.92; 506/2:435/6.11; (73) Assignee: Veracyte, Inc., South San Francisco, CA 435/6.12: 514/345; 506/16; 514/263.2: 514/562; (US) 702/20 Appl. No.: 14/213,632 (21) (57) ABSTRACT (22) Filed: Mar 14, 2014 The present disclosure provides methods for diagnosis of interstitial lung diseases (ILDS). The present disclosure pro Related U.S. Application Data vides methods for differential diagnosis of idiopathic pulmo (60) Provisional application No. 61/799,754, filed on Mar. nary fibrosis from other ILDs. Compositions and kits useful 15, 2013. in carrying out a Subject method are also provided. Patent Application Publication Dec. 25, 2014 Sheet 1 of 129 US 2014/0378425 A1 Figure 1 DataSet N is 84 3 x 383r x ladiag M. simir SF s Symline artixedcost Lipids: s: if geries Patent Application Publication Dec. 25, 2014 Sheet 2 of 129 US 2014/0378425 A1 eODS Patent Application Publication Dec. 25, 2014 Sheet 3 of 129 US 2014/0378425 A1 Figure 3 Dataset N is 89 i - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . Siar s Ed's s 8 - f 4 is genes Patent Application Publication Dec. 25, 2014 Sheet 4 of 129 US 2014/0378425 A1 e ODS Patent Application Publication Dec. 25, 2014 Sheet 5 of 129 US 2014/0378425 A1 Figure 5 inpitats 3 $80 -. y : 8 w w w w w w w w w w w w w ' ' ' ' ' ' ' ' ''' ------------------------------------------------ - " - ips: ress Eterface wists r x-r irr 3. -------------------------------------------'-'.'.or orggro-r3ts mor, ... 88: Batatase 3. : : Storage 8wice : to- ---------------------------------------------- Ottp:st Cata Patent Application Publication Dec. 25, 2014 Sheet 6 of 129 US 2014/0378425 A1 Figure 6A Differentially expressed genes between IPF and NSIP using Microarray data. Comprehensive list of markers based on significance (FDR pro.05). A total of 495 markers were found to be significant with this analysis. Log2 fold changes of genes overexpressed in PF as compared to NSIP range from 0.30 to 1.87. Log2 fold changes of genes underexpressed in EPF as compared to NSEP range from -2.43 to -0.28. Overexpressed: ACACB, ACTA2, ACTG2, ADARB1, AHNAK2, AMOT, ANO!, ANO2, ANTXR1, AOC3, ARHGAP 10, ARHGEF25, ATP1A2, ATP B2, Corf 15, C2orf40, C7orf4 C8orf84, CALD, CAP2, CASQ2, CDC42BPA, CDH13, CDH6, CFC B, CNN1, CNTN4, COL21A1, CORO2B, COX7A, CREM, CRIP2, CRYAB, CXorf69, DAAM1, DENND2A, DES, DGKG, DEXDC, DMD, DST, EDIL3, EFHD1, EXOC6B, FABP4, FAM13C, FAM21C, FBXL2, FHL}, FHL5, FRY, GARNL3, GNA, HEY2, HRCTI, HSPB7, HTRF, ICAL, IGF1R, IGFBP5, ITGB4, JAG1, KALRN, KANK2, KIAA 1377, LGR4, LHFP, LMCD1, LMOD1, LPHN3, LRRFP1, LTBP4, LY6G6C, MAP B, MAP7 D3, MARK1, MPDZ, MSRB3, MUSTN MXRA7, MYH MYL9, MYLK, MYOCD, MYOM1, NBPF 10, NDRG2, NET, NEXN, NKD 1, PALLD, PALMD, PARD3B, PBX). PCDHB10, PCDHB3, PDEC, PDE2A, PDE5A, PEG3, PGM5, PHLDB2, PHY HIPL, PKD2, PKIG, PLCB4, PLCE, PLEKHH2, PLN, PPARGC1A, PPFIBP1, PPML, PPP1R 14A, PPP1R3C, PRDMS, PRELP, PREX2, PRKAA2, PRKG 1 PRUNE2, PTCHD4, PTPN14, PTPN2, PTRF, RBM24, RBMS3, REP 15, RGS7BP, RNF180, ROCK2, SDC2, SLN, SORBS1, SUN, SVIL, SYNM, SYNPO2, TAGLN, TBC1D19, TCID-7895852, TCID-7919146, TCID-7981986, TCID-7981988, TCTD-798.1990, TCID-7996260, TCID-8027746, TCID-8031646, TCID-8124498, TCID-8161520, THRA, TEMP3, TMEM47, TNS, TPM1, TPM2, TRPC1, TTLL7, USP2, WDR52, WDR60, ZC3H2B, ZFP28, ZFYVE9, ZNF221, ZNF45, ZNF461, ZNF483, ZNF879, Patent Application Publication Dec. 25, 2014 Sheet 9 of 129 US 2014/0378425 A1 Figure 8 Differentially expressed genes between IPF and NSIP using RNA-Seq, Comprehensive list of markers based on NPSeq analysis of RNASeq data. A total of 160 markers were found to be significant with this analysis. Log2 fold changes of genes overexpressed in IPF as compared to NSP range from 0, 15 to .95. Log2 fold changes of genes underexpressed in IPF as compared to NSP range from -2.30 to -0. 4. Overexpressed. ABI2, AHNAK, AKAP6, AKR1C3, AMOT, AXL, BMPR1A Clorf168, C2Orf40, C5orf4, C7orf58, C8orf84, C9arf25, CAP2, COLAA5, COLAA6, CPQ, CSRP1, DNAJC19, ENSG00000149531, ENSG0000020948. FAM189A1, FAM63B, FHL, FMO2, GAS6, GSTM3. LGR4, LGR6, LIMS2, LMOD1, MSRB3, MXRA7, NACC2, NEK7, NKD 1, NPTXR, NXPH3, NYNRIN, OMA, PALLD, PARD3B, PDFC, PHLDA3, PPML, PPP1R3C, PTCHD4, RBMS3, RSPH3, SCD5, SEPT7, SKAP2, SLC1A7, SVEL, SYNC, TIMP3. TPM1, TRNP, TTLL7, UGP2, ZNF583, ZNF607, ZNF615, ZNF880. Underexpressed, AASS, ABCA3, ACADSB, ACPP, ACSM3, ACSS2, ANLN, ARHGEF38, ATP2C2, B4GALT3, CA 3, CCNF, CDKL2, CEP55, CFTR, CHEK, CISH, COPG, CREB3L1, CSF3R, CXCL17, CXCL3, DERL), DRAM1, DUSP16, EDEM1, ENSG00000137700, ENSG00000224189, ENSG00000225431, ENSG00000228863, ENSG00000248801, ENSG00000248890, ENSG 00000256039, ERN, FADSi, FADS2, FAM20A, FAM40B, FASN, GBF1, HK2, HM13, HOXD1, IL8, KCNQ3, KIF 14, KIF 8B, KIF4A, LAD1, LAMP3, MACROD2, MAPK13, METTL7B, MTRR, MUC21, NUP50, ORM1, PDZK1 EP, PMAIP1, PNKD, POLR2C, POU2F3, PPP1R1B. R3HDMI, RGS16, ROS1, SCN1A, SCTR, SDR16C5, SEC24D, SEMA4A, SERPINA 1 SFTPD, SFXN1, SFXN2, SIAE, SLC5A8, SLC7A 11, SLC7A5, SMC4, SOD2, SRSF6. ST8SIA4, SURF4, TBC1D24, TDRKH, TLR2, TNIP3, TOP2A, TOX, TROAP. TST, TTC39A, YARS, ZDHHC18, ZNF238. Patent Application Publication Dec. 25, 2014 Sheet 19 of 129 US 2014/0378425A1 Figure 10F Underexpressed (continued) TCID-7894200, TCID-7894204, TCID-7894285, TCID-7894355, TCID-7894482, TCID-7894537, TCID-7894562, TCID-7894.575, TCID-7894.639, TCID-7894752, TCID-7895.080, TCID-7895.098, CID-7895.25. TCD-7895153, TCID-7895.223, CD-7895.308, TCD-7895362, TCID-7895.381, TCID-7895.384, TCID-789S448, TCID-7895.505, TCID-7895536, TCID-7895581, TCID-7895.603, TCID-7895751. TCID-7895847, TCID-7895957, TCID-7896098, TCID-7896275, TCID-7896393, TCD-78964 13, TCID-7896439, TCID-7896598, TCID-7896632, TCID-789664, TCID-7896659, TCID-7902685, TCID-7904.048, TCID-7904953, TCID-79.05731, TCID-79 13803, TCID-7914214, TCID-79 6781. TCD-7918048, TCID-7919594, TCD-79.9747, TCID-7919749, TCID-7922523, TCID-7926484, TCID-7927595, TCID-7927704, TCID-7928367, TCID-793.0915, TCID-7932552, TCID-79378.90, TCID-793.8258, TCID-793.8293, TCID-7938.681, TCID-7939.902, TCID-794.0717, ICED-794196). TCD-7942061, TCID-7942877, TCED-794460, TCD-7945942, TCID-794632, TCID-7951339, TCID-7952737, TCID-7953977, TCID-7954310, TCID-795.8826, TCID-796.0338, TCID-796052, TCID-796054, TCID-7961602, TCID-7962341, TCID-7965036. TCID-7965. 10, TCED-7968232, TCID-7969339, TCID-7969531, TCID-7969638, TCID-7970082, TCID-797 1998. TCD-7972803, TCID-7974008, TCID-7974.027, TCID-7974.029, TCID-7975813, TCID-7980906, TCID-798.3054, TCID-7983951, TCID-7989883, TCID-7990755, TCID-799 1171, TCID-7993 179, TCID-7994.091, TCID-7995.377, TCID-7999362, TCID-7999476, TCID-8003075, TCID-8005626, TCID-8005753, TCID-80.11678, TCID-80 13013, TCID-80 13329, TCID-80 13356, TCID-8013523, ICD-805757. TCD-80 19088, TCID-80957, TCED-809709, TCD-8020139, TCID-8020239, TCID-8022243, TCID-8022378, TCID-80225.06, TCID-8022557. TCED-8024566, TCID-8027354, TCID-803566, TCID-8034694, TCID-8037387, TCID-8039084, TCID-8042219, TCID-8042464, TCD-8043498, TCID-8043993, TCID-8045341, TCID-8045343, TCD-8045533, TCID-8045804. TCID-80460:8, TCID-8050213, TCID-8051812, TCID-8054607, TCID-8055348, TCID-8055486, TCID-8056359, TCID-8059744, TCED-8061414, TCID-8063026. TCED-8063408, TCID-8064,857, TCID-8065134, TCID-8065363, TCID-8065756, TCID-8066275, TCID-8066983, TCID-8067877, TCED-8069768, TCID-8071204, TCID-8073680, TCID-8074714, TCID-8074716, TCID-8075693, TCD-8077499, TCD-8082605, TCED-8083455, TCID-8083492, TCID-8083592, TCID-8083848, TCID-8083.893, TCID-8084739, TCD-8090674, TCID-8091 101, TCID-8091444, TCID-8092390, TCID-8093451, TCID-8093974, TCID-8094026, TCID-8094,340, TCID-8094776, TCID-809559, TCID-80322, TCID-802230, TCID-8103975, TCID-8104568, TCID-810607, TCID-8108013, TCD-8108977. TCD-8 12335, TCED-81 12666, TCD-81 13717, TCID-8 14812, TCED-81 15664, TCID-8 15679, TCID-81 16992, TCED-8 7712, TCD-820820, TCID-8 2390, TCID-812 1884, TCD-8122 198, TCID-8122701, TCID-823340, TCID-8123407, TCID-827662, TCID-8127752. TCID-8131512, TCID-8132290, TCID-8132998, TCID-8133070, TCID-8133106, TCID-8133688, TCID-8135585. TCID-8137483, TCID-839816, TCD-8143365, TCID-8:45083, TCID-81.45795, TCID-84639, TCID-8146857, TCID-8 47373, TCD-847990, TCID-81.48040, TCID-8150689, TCID-8150862, TCID-8153041, TCID-815432, TCID-8154719, TCID-8154838, TCID-8155026, TCID-8155376. TCD-8156358, TCID-8160767, TCID-81 61000, TCID-8 62645, TCID-8163710, TCID-8164694, TCID-8165255, TCID-8165646, TCID-8165656, TCID-8: 65658, TCID-8165696, TCID-8681 15, TCID-86936, TCED-8 7098, TCD-87 18O, TCID-8 72082, TCID-8 172266, TCID-817.3156, TCID-8173924. TCTEX1D4, TEAD4, TEK, TFPI, TGIF1, THBD, THSD1, TIPARP, TKT, TLCD1, TLR2, TLR3, TM7SF2, TM7SF4, TMEM100, TMEM116, TMEM125, TMEM130, TMEM139, TMEM14, TMEM16B. TMEM164, TMEM170A, TMEM180, TMEM2, TMEM242, TMEM30B, TMEM41B, TMEM45B, TMEM53, TMEM87A, TMEM88, TMEM97, TMPO, TMPRSS2, TMSB15A, TNFSF10, TNNC, TNNI2. TNNE3, TNNT1, TNNT2, TNS3, TOML Patent Application Publication Dec. 25, 2014 Sheet 27 of 129 US 2014/0378425A1 Figure 12 Differentially expressed genes between NSIP and HP using Microarray data. Markers were selected based on significance (p<0.05) after Benjamini and Hochberg correction for false discovery rate (FDR).
Load more

Recommended publications
  • Role of Proteases in Dysfunctional Placental Vascular Remodelling in Preeclampsia
    Accepted Manuscript Role of proteases in dysfunctional placental vascular remodelling in preeclampsia Jaime A. Gutiérrez, Isabel Gómez, Delia I. Chiarello, Rocío Salsoso, Andrés D. Klein, Enrique Guzmán-Gutiérrez, Fernando Toledo, Luis Sobrevia PII: S0925-4439(19)30115-2 DOI: https://doi.org/10.1016/j.bbadis.2019.04.004 Reference: BBADIS 65448 To appear in: BBA - Molecular Basis of Disease Received date: 23 February 2018 Revised date: 20 December 2018 Accepted date: 6 January 2019 Please cite this article as: J.A. Gutiérrez, I. Gómez, D.I. Chiarello, et al., Role of proteases in dysfunctional placental vascular remodelling in preeclampsia, BBA - Molecular Basis of Disease, https://doi.org/10.1016/j.bbadis.2019.04.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Role of proteases in dysfunctional placental vascular remodelling in preeclampsia Jaime A. Gutiérrez1,7 *, Isabel Gómez1, Delia I Chiarello7, Rocío Salsoso5,7†, Andrés D Klein2, Enrique Guzmán-Gutiérrez3, Fernando Toledo4,7, Luis Sobrevia5,6,7 * 1 Cellular Signaling and Differentiation Laboratory (CSDL), School of Medical Technology, Health Sciences Faculty, Universidad San Sebastián, Santiago 7510157, Chile. 2 Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7590943, Chile.
    [Show full text]
  • ADAMTS Proteases in Vascular Biology
    Review MATBIO-1141; No. of pages: 8; 4C: 3, 6 ADAMTS proteases in vascular biology Juan Carlos Rodríguez-Manzaneque 1, Rubén Fernández-Rodríguez 1, Francisco Javier Rodríguez-Baena 1 and M. Luisa Iruela-Arispe 2 1 - GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain 2 - Department of Molecular, Cell, and Developmental Biology, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA Correspondence to Juan Carlos Rodríguez-Manzaneque and M. Luisa Iruela-Arispe: J.C Rodríguez-Manzaneque is to be contacted at: GENYO, 15 PTS Granada - Avda. de la Ilustración 114, Granada 18016, Spain; M.L. Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, UCLA, 615 Charles Young Drive East, Los Angeles, CA 90095, USA. [email protected]; [email protected] http://dx.doi.org/10.1016/j.matbio.2015.02.004 Edited by W.C. Parks and S. Apte Abstract ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15 years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise.
    [Show full text]
  • Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin
    The Journal of Neuroscience, March 22, 2017 • 37(12):3181–3191 • 3181 Cellular/Molecular Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin Himari Ogino,1* Arisa Hisanaga,1* XTakao Kohno,1 Yuta Kondo,1 Kyoko Okumura,1 Takana Kamei,1 Tempei Sato,2 Hiroshi Asahara,2 Hitomi Tsuiji,1 Masaki Fukata,3 and Mitsuharu Hattori1 1Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan, 2Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan, and 3Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Aichi 444-8787, Japan The secreted glycoprotein Reelin regulates embryonic brain development and adult brain functions. It has been suggested that reduced Reelin activity contributes to the pathogenesis of several neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer’s disease; however, noninvasive methods that can upregulate Reelin activity in vivo have yet to be developed. We previously found that the proteolytic cleavage of Reelin within Reelin repeat 3 (N-t site) abolishes Reelin activity in vitro, but it remains controversial as to whether this effect occurs in vivo. Here we partially purified the enzyme that mediates the N-t cleavage of Reelin from the culture supernatant of cerebral cortical neurons. This enzyme was identified as a disintegrin and metalloproteinase with thrombospondin motifs-3 (ADAMTS-3). Recombinant ADAMTS-3 cleaved Reelin at the N-t site. ADAMTS-3 was expressed in excitatory neurons in the cerebral cortex and hippocampus.
    [Show full text]
  • An Advance About the Genetic Causes of Epilepsy
    E3S Web of Conferences 271, 03068 (2021) https://doi.org/10.1051/e3sconf/202127103068 ICEPE 2021 An advance about the genetic causes of epilepsy Yu Sun1, a, *, †, Licheng Lu2, b, *, †, Lanxin Li3, c, *, †, Jingbo Wang4, d, *, † 1The School of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801-3633, US 2High School Affiliated to Shanghai Jiao Tong University, Shanghai, 200441, China 3Applied Biology program, University of British Columbia, Vancouver, V6r3b1, Canada 4School of Chemical Machinery and Safety, Dalian University of Technology, Dalian, 116023, China †These authors contributed equally. Abstract: Human hereditary epilepsy has been found related to ion channel mutations in voltage-gated channels (Na+, K+, Ca2+, Cl-), ligand gated channels (GABA receptors), and G-protein coupled receptors, such as Mass1. In addition, some transmembrane proteins or receptor genes, including PRRT2 and nAChR, and glucose transporter genes, such as GLUT1 and SLC2A1, are also about the onset of epilepsy. The discovery of these genetic defects has contributed greatly to our understanding of the pathology of epilepsy. This review focuses on introducing and summarizing epilepsy-associated genes and related findings in recent decades, pointing out related mutant genes that need to be further studied in the future. 1 Introduction Epilepsy is a neurological disorder characterized by 2 Malfunction of Ion channel epileptic seizures caused by abnormal brain activity. 1 in Functional variation in voltage or ligand-gated ion 100 (50 million people) people are affected by symptoms channel mutations is a major cause of idiopathic epilepsy, of this disorder worldwide, with men, young children, and especially in rare genetic forms.
    [Show full text]
  • Identi Ed a Disintegrin and Metalloproteinase with Thrombospondin Motifs 6 Serve As a Novel Gastric Cancer Prognostic Biomarker
    Identied a Disintegrin and Metalloproteinase with Thrombospondin Motifs 6 Serve as a Novel Gastric Cancer Prognostic Biomarker by Integrating Analysis of Gene Expression Prole Ya-zhen Zhu GuangXi University of Chinese Medicine https://orcid.org/0000-0001-6932-698X Yi Liu Guangxi Cancer Hospital and Guangxi Medical University Aliated Cancer Hospital Xi-wen Liao Guangxi Cancer Hospital and Guangxi Medical University Aliated Cancer Hospital Xian-wei Mo Guangxi Cancer Hospital and Guangxi Medical University Aliated Cancer Hospital Yuan Lin Guangxi Cancer Hospital and Guangxi Medical University Aliated Cancer Hospital Wei-zhong Tang Guangxi Cancer Hospital and Guangxi Medical University Aliated Cancer Hospital Shan-shan Luo ( [email protected] ) Research article Keywords: ADAMTS, mRNA, gastric cancer, prognosis Posted Date: July 14th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-41038/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/31 Abstract Objective: We aimed to explore the prognostic value of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) genes in gastric cancer (GC). Methods: The RNA-sequencing (RNA-seq) expression data for 351 GC patients and other relevant clinical data was acquired from The Cancer Genome Atlas (TCGA). Survival analysis and a genome-wide gene set enrichment analysis (GSEA) were performed to dene the underlying molecular value of the ADAMTS genes in GC development. Results: The Log rank test with both Cox regression and Kaplan–Meier survival analysis showed that ADAMTS6 expression prole correlated with the GC patients’ clinical outcome. Patients with a high expression of ADAMTS6 were associated with poor overall survival (OS).
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • Proteolytic Activation Defines Distinct Lymphangiogenic Mechanisms for VEGFC and VEGFD
    Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD Hung M. Bui, … , Kari Alitalo, Mark L. Kahn J Clin Invest. 2016;126(6):2167-2180. https://doi.org/10.1172/JCI83967. Research Article Vascular biology Lymphangiogenesis is supported by 2 homologous VEGFR3 ligands, VEGFC and VEGFD. VEGFC is required for lymphatic development, while VEGFD is not. VEGFC and VEGFD are proteolytically cleaved after cell secretion in vitro, and recent studies have implicated the protease a disintegrin and metalloproteinase with thrombospondin motifs 3 (ADAMTS3) and the secreted factor collagen and calcium binding EGF domains 1 (CCBE1) in this process. It is not well understood how ligand proteolysis is controlled at the molecular level or how this process regulates lymphangiogenesis, because these complex molecular interactions have been difficult to follow ex vivo and test in vivo. Here, we have developed and used biochemical and cellular tools to demonstrate that an ADAMTS3-CCBE1 complex can form independently of VEGFR3 and is required to convert VEGFC, but not VEGFD, into an active ligand. Consistent with these ex vivo findings, mouse genetic studies revealed that ADAMTS3 is required for lymphatic development in a manner that is identical to the requirement of VEGFC and CCBE1 for lymphatic development. Moreover, CCBE1 was required for in vivo lymphangiogenesis stimulated by VEGFC but not VEGFD. Together, these studies reveal that lymphangiogenesis is regulated by two distinct proteolytic mechanisms of ligand activation: one in which VEGFC activation by ADAMTS3 and CCBE1 spatially and temporally patterns developing lymphatics, and one in which VEGFD activation by a distinct […] Find the latest version: https://jci.me/83967/pdf The Journal of Clinical Investigation RESEARCH ARTICLE Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD Hung M.
    [Show full text]
  • Understanding the Genetics and Neurobiological Pathways Behind Addiction (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 544, 2021 Understanding the genetics and neurobiological pathways behind addiction (Review) ALEXANDRA POPESCU1, MARIA MARIAN1*, ANA MIRUNA DRĂGOI1* and RADU‑VIRGIL COSTEA2* 1Department of Psychiatry, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital of Psychiatry, 041914 Bucharest; 2Department of General Surgery, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania Received January 15, 2021; Accepted February 15, 2021 DOI: 10.3892/etm.2021.9976 Abstract. The hypothesis issued by modern medicine states 1. Introduction that many diseases known to humans are genetically deter‑ mined, influenced or not by environmental factors, which is Substance‑related disorders are a set of behavioral, cognitive applicable to most psychiatric disorders as well. This article and physiological phenomena that occur after repeated use of a focuses on two pending questions regarding addiction: substance. These typically include: A strong desire to continue Why do some individuals become addicted while others do using a drug, difficulties in controlling its use, persistence in not? along with Is it a learned behavior or is it genetically using it although it has negative consequences, the use of the predefined? Recent data suggest that addiction is more than substance taking precedence over other activities and obliga‑ repeated exposure, it is the synchronicity between intrinsic tions, along with high tolerance and sometimes withdrawal (1). factors (genotype, sex, age, preexisting addictive disorder, New developments have altered the way we define addiction. or other mental illness), extrinsic factors (childhood, level of In this sense the Diagnostic and Statistical Manual of Mental education, socioeconomic status, social support, entourage, Disorders (5th ed.) (DSM‑5) (2) has changed the related chapter drug availability) and the nature of the addictive agent (phar‑ from ‘Substance‑Related Disorders’ to ‘Substance‑Related macokinetics, path of administration, psychoactive properties).
    [Show full text]
  • Download (PDF)
    Supplemental Information Biological and Pharmaceutical Bulletin Promoter Methylation Profiles between Human Lung Adenocarcinoma Multidrug Resistant A549/Cisplatin (A549/DDP) Cells and Its Progenitor A549 Cells Ruiling Guo, Guoming Wu, Haidong Li, Pin Qian, Juan Han, Feng Pan, Wenbi Li, Jin Li, and Fuyun Ji © 2013 The Pharmaceutical Society of Japan Table S1. Gene categories involved in biological functions with hypomethylated promoter identified by MeDIP-ChIP analysis in lung adenocarcinoma MDR A549/DDP cells compared with its progenitor A549 cells Different biological Genes functions transcription factor MYOD1, CDX2, HMX1, THRB, ARNT2, ZNF639, HOXD13, RORA, FOXO3, HOXD10, CITED1, GATA1, activity HOXC6, ZGPAT, HOXC8, ATOH1, FLI1, GATA5, HOXC4, HOXC5, PHTF1, RARB, MYST2, RARG, SIX3, FOXN1, ZHX3, HMG20A, SIX4, NR0B1, SIX6, TRERF1, DDIT3, ASCL1, MSX1, HIF1A, BAZ1B, MLLT10, FOXG1, DPRX, SHOX, ST18, CCRN4L, TFE3, ZNF131, SOX5, TFEB, MYEF2, VENTX, MYBL2, SOX8, ARNT, VDR, DBX2, FOXQ1, MEIS3, HOXA6, LHX2, NKX2-1, TFDP3, LHX6, EWSR1, KLF5, SMAD7, MAFB, SMAD5, NEUROG1, NR4A1, NEUROG3, GSC2, EN2, ESX1, SMAD1, KLF15, ZSCAN1, VAV1, GAS7, USF2, MSL3, SHOX2, DLX2, ZNF215, HOXB2, LASS3, HOXB5, ETS2, LASS2, DLX5, TCF12, BACH2, ZNF18, TBX21, E2F8, PRRX1, ZNF154, CTCF, PAX3, PRRX2, CBFA2T2, FEV, FOS, BARX1, PCGF2, SOX15, NFIL3, RBPJL, FOSL1, ALX1, EGR3, SOX14, FOXJ1, ZNF92, OTX1, ESR1, ZNF142, FOSB, MIXL1, PURA, ZFP37, ZBTB25, ZNF135, HOXC13, KCNH8, ZNF483, IRX4, ZNF367, NFIX, NFYB, ZBTB16, TCF7L1, HIC1, TSC22D1, TSC22D2, REXO4, POU3F2, MYOG, NFATC2, ENO1,
    [Show full text]
  • A Bioinformatics Model of Human Diseases on the Basis Of
    SUPPLEMENTARY MATERIALS A Bioinformatics Model of Human Diseases on the basis of Differentially Expressed Genes (of Domestic versus Wild Animals) That Are Orthologs of Human Genes Associated with Reproductive-Potential Changes Vasiliev1,2 G, Chadaeva2 I, Rasskazov2 D, Ponomarenko2 P, Sharypova2 E, Drachkova2 I, Bogomolov2 A, Savinkova2 L, Ponomarenko2,* M, Kolchanov2 N, Osadchuk2 A, Oshchepkov2 D, Osadchuk2 L 1 Novosibirsk State University, Novosibirsk 630090, Russia; 2 Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russia; * Correspondence: [email protected]. Tel.: +7 (383) 363-4963 ext. 1311 (M.P.) Supplementary data on effects of the human gene underexpression or overexpression under this study on the reproductive potential Table S1. Effects of underexpression or overexpression of the human genes under this study on the reproductive potential according to our estimates [1-5]. ↓ ↑ Human Deficit ( ) Excess ( ) # Gene NSNP Effect on reproductive potential [Reference] ♂♀ NSNP Effect on reproductive potential [Reference] ♂♀ 1 increased risks of preeclampsia as one of the most challenging 1 ACKR1 ← increased risk of atherosclerosis and other coronary artery disease [9] ← [3] problems of modern obstetrics [8] 1 within a model of human diseases using Adcyap1-knockout mice, 3 in a model of human health using transgenic mice overexpressing 2 ADCYAP1 ← → [4] decreased fertility [10] [4] Adcyap1 within only pancreatic β-cells, ameliorated diabetes [11] 2 within a model of human diseases
    [Show full text]